TNFSF9 Is Associated with Favorable Tumor Immune Microenvironment in Patients with Renal Cell Carcinoma Who Are Treated with the Combination Therapy of Nivolumab and Ipilimumab.
Int J Mol Sci
; 25(13)2024 Jul 06.
Article
in En
| MEDLINE
| ID: mdl-39000552
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Carcinoma, Renal Cell
/
Tumor Microenvironment
/
Ipilimumab
/
Nivolumab
/
Kidney Neoplasms
Limits:
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Int J Mol Sci
Year:
2024
Document type:
Article
Affiliation country:
Japón
Country of publication:
Suiza